Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia
Antonio Vitiello, Francesco Ferrara, Chiara Pelliccia, G. Granata, Raffaele La Porta
Abstract
For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus itself, but by an overactive inflammatory state. In fact, in some people the immune system goes into overdrive and launches a large-scale assault on the tissue known as cytokine storm. This excessive inflammatory/immune reaction can damage tissue and eventually kill people. Evidence shows that blocking such cytokine storms can be effective and trials are underway to test drugs that act by reducing cytokine response, such as tocilizumab and sarilumab which bind interleukin 6 (IL-6), or anikinra which is the interleukin 1 receptor antagonist (IL-1). However, other drugs that block the cytokine cascade can also be considered. In this article we describe the scientific and molecular motivation for the use of drugs that act by modulating the hyperactive inflammatory system in severe patients suffering from SARS-CoV-2, considering in particular an old drug that has been in use for many years for other therapeutic indications such as colchicine, and that could be favourable to its use, with low cost and good tolerability.